Skip to main content
AMLX logo

AMLX · Amylyx Pharmaceuticals, Inc.

$18.50 +1.05 (+6.02%) At close · Jul 21
Market Cap
$2.06B
Shares
111.19M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Justin Klee $2,719,807
Joshua Cohen $2,719,807
Camille Bedrosian $1,567,674
James Frates $1,375,327
Fiscal 2024
Executive Total
Joshua Cohen $6,496,255
Justin Klee $6,496,255
James Frates $2,540,353
Gina M. Mazzariello $2,298,996
Fiscal 2023
Executive Total
Joshua Cohen $7,418,169
Justin Klee $7,418,169
James Frates $3,510,377
Margaret Olinger $3,447,150
Gina M. Mazzariello $3,013,676
Camille Bedrosian $2,372,859
Fiscal 2022
Executive Total
Justin Klee $7,178,416
Joshua Cohen $7,178,416
Gina M. Mazzariello $6,113,548
James Frates $3,658,945
Margaret Olinger $2,995,817
Fiscal 2021
Executive Total
James Frates $3,255,900
Justin Klee $1,424,533
Joshua Cohen $1,424,533
Margaret Olinger $863,398
Fiscal 2020
Executive Total
Justin Klee $670,500
Joshua Cohen $670,500
Margaret Olinger $515,036
Key facts CIK 1658551 CUSIP 03237H101 13F (30d) 10 filings 10 filers Visit website Investor relations